Mammoth Rx Inc. – Trademark Portfolio

Entity Type: 03

Mammoth Rx Inc. holds 4 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 35 (Advertising & Business) — 3 filings in this category. The portfolio also extends into Class 5 (Pharmaceuticals) across 2 Nice Classification classes. Currently, 2 trademarks are registered. Notable registered marks include MAMMOTH and MAMMOTH RX. The owner is based in San Diego, CA.

10815 Rancho Bernardo Rd, Suite 300

San Diego, CA 92127

4 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

ROOTS
ROOTS
Abandoned 2023
MAMMOTH
MAMMOTH
Registered 2022

Trademark Classifications

Mammoth Rx Inc.'s trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.

35
Advertising & Business (3 filings)

Advertising; business management; business administration; office functions

5
Pharmaceuticals (1 filing)

Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes

Frequently Asked Questions

How many trademarks does Mammoth Rx Inc. have?

Mammoth Rx Inc. has 4 U.S. trademarks filed with the USPTO. Of these, 2 registered, 2 abandoned.

What trademark classes does Mammoth Rx Inc. file in?

Mammoth Rx Inc. files trademarks across 2 Nice Classification classes. The most active classes are Class 35 (Advertising & Business), Class 5 (Pharmaceuticals). Class 35 covers advertising; business management; business administration; office functions.

What are Mammoth Rx Inc.'s most well-known trademarks?

Mammoth Rx Inc.'s registered trademark portfolio includes well-known marks such as MAMMOTH and MAMMOTH RX. These are among 2 currently registered trademarks in the portfolio.

What is Mammoth Rx Inc.'s trademark registration success rate?

Mammoth Rx Inc. has a 50% trademark registration rate, with 2 out of 4 resolved applications resulting in successful registration. Currently, 0 applications are pending review.